Abstract 75P
Background
Adebrelimab is a novel humanised IgG4 monoclonal antibody against PD-L1, indicated for the first-line treatment of adult Patients with ES-SCLC in China. A registry study was conducted with the use of disease-specific database of lung cancer, at 21 Centres in Jiangsu, China. Here, we report results of Cohort ADBL-LC-001: the efficacy and safety of adebrelimab in the first-line treatment of patients with SCLC.
Methods
We prospectively collected medical records from patients with SCLC, who initiated first-line treatment with adebrelimab. Primary endpoint is progression-free survival (PFS) by RECIST 1.1, secondary endpoints included overall survival (OS), objective response rate (ORR) , disease control rate (DCR) and safety.
Results
Between March 2023 and March 2024, 143 patients were included, the median follow-up was 10.3 months. Overall, 114(80%) patients were ES-SCLC and 29(80%) LS-SCLC, median age was 67 years (rang, 34-84), and most patients were ≥65 years (62%), male (78%), with an ECOG score of one (90%). 29 (25%) patients with ES-SCLC had liver metastases, 23 (20%) had Brain metastases. In the group ES-SCLC, mOS was 12.4 months (95% CI, 10.0-14.9) and mPFS was 6.7 months (95% CI, 5.3-7.7), the ORR, DCR was 34.2%, 85.1%, respectively. In the group LS-SCLC, mOS was 15.4 months (95% CI, 13.7-NA) and mPFS was 14.6 months (95% CI, 13.4-15.4), the ORR, DCR was 51.7%, 96.6%, respectively. In the IIT population, TEAEs occurred in 136 (95.1%) patients, grade 3 or worse TEAEs occurred in 29 (20.3%) patients. The most common grade ≥ 3 TEAEs were neutrophil count decreased (8.4%), lymphocyte count decreased (5.6%), anemia (3.5%), white blood cell decreased (2.8%), γ-glutamyltransferase increased (2.8%). The safety profile was generally manageable, without any unexpected adverse events. Table: 75P
The most common adverse events (incidence>20%)
AEs, n(%) | ES-SCLC(N=114) | LS-SCLC(N=29) | Total(N=143) | |||
Any gade | Gade ≥ 3 | Any gade | Gade ≥ 3 | Any gade | Gade ≥ 3 | |
All gade | 110 (96.5%) | 26 (22.8%) | 26 (89.7%) | 3 (10.3%) | 136 (95.1%) | 29 (20.3%) |
Anemia | 74 (64.9%) | 4 (3.5%) | 21 (72.4%) | 1 (3.5%) | 95 (66.4%) | 5 (3.5%) |
Lymphocyte count decreased | 51 (44.7%) | 8 (7.0%) | 15 (51.7%) | 0 | 66 (46.2%) | 8 (5.6%) |
Hypoalbuminemia | 51 (44.7%) | 1 (0.8%) | 7 (24.1%) | 0 | 58 (40.6%) | 1 (0.7%) |
White blood cell decreased | 35 (30.7%) | 4 (3.5%) | 5 (17.2%) | 0 | 40 (28.0%) | 4 (2.8%) |
Nausea | 29 (25.4%) | 0 | 10 (34.5%) | 0 | 39 (27.3%) | 0 |
Neutrophil count decreased | 29 (25.4%) | 11 (9.7%) | 9 (31.0%) | 1 (3.5%) | 36 (25.2%) | 12 (8.4%) |
Fever | 13 (11.4%) | 0 | 10 (34.5%) | 0 | 13 (9.1%) | 0 |
Conclusions
This Real-world data verified the efficacy and safety of adebrelimab in the first-line treatment of patients with SCLC.
Legal entity responsible for the study
The authors.
Funding
Jiangsu Hengrui Pharmaceutical Co. LTD.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
135P - Efficacy and safety of tislelizumab combined with bronchial arterial infusion (BAI) chemotherapy in potentially resectable stage IIIB non-small cell lung cancer(NSCLC): A prospective, single-arm phase II clinical study
Presenter: Xu Ma
Session: Poster Display session
Resources:
Abstract
136P - Tislelizumab (TIS) plus chemotherapy (chemo) with or without bevacizumab (beva) for patients with EGFR-mutated nonsquamous NSCLC (nsq-NSCLC) after progression on EGFR tyrosine kinase inhibitor (TKI) therapy: An updated analysis
Presenter: Baohui Han
Session: Poster Display session
Resources:
Abstract
137P - Hepatic arterial infusion chemotherapy combined with lenvatinib and tislelizumab for unresectable hepatocellular carcinoma: A single-arm, phase II study
Presenter: Jianbing Wu
Session: Poster Display session
Resources:
Abstract
138P - Interim results of neoadjuvant TACE plus lenvatinib and tislelizumab in resectable HCC at CNLC stages IB and IIA with high-risk of recurrence: A prospective, single-arm, phase II trial
Presenter: Yuhua Zhang
Session: Poster Display session
Resources:
Abstract
139P - Ablation combined with tislelizumab in treating hepatocellular carcinoma: A phase II trial
Presenter: Yangxun Pan
Session: Poster Display session
Resources:
Abstract
140P - Tislelizumab combined with lenvatinib and transarterial chemoembolization(TACE) neoadjuvant treatment in resectable CNLC IIa-IIb hepatocellular carcinoma: A prospective, single-arm, phase II study
Presenter: Zhibo Zhang
Session: Poster Display session
Resources:
Abstract
141P - Efficacy and safety of tislelizumab(T) combined with gemcitabine and cisplatin(GC) for patients with localized muscle-invasive bladder cancer(MIBC) after radical local surgery: A prospective, phase II study
Presenter: Ming Cao
Session: Poster Display session
Resources:
Abstract
143P - Strength of patient (pt) preference for atezolizumab (atezo) subcutaneous (SC) vs intravenous (IV) for the treatment of NSCLC: exploratory analyses from the IMscin002 study
Presenter: Margarita Majem Tarruella
Session: Poster Display session
Resources:
Abstract
144P - First-line cemiplimab monotherapy for advanced non-small cell lung cancer (NSCLC) of squamous histology: Subgroup analysis with 5-year results from EMPOWER-Lung 1
Presenter: Tamta Makharadze
Session: Poster Display session
Resources:
Abstract
145P - Penpulimab-based combination neoadjuvant/adjuvant therapy for patients with resectable locally advanced non-small cell lung cancer: An update of the phase II, prospective study (ALTER-L043)
Presenter: Changli Wang
Session: Poster Display session
Resources:
Abstract